Blog
General Motors Set to Report Q3 Earnings: Here's What to Expect
General Motors GM is slated to release third-quarter 2025 results on Oct. 21, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings and revenues is pegged
UPS Stock Trades Near 52-Week Low: Time to Buy, Sell or Hold?
United Parcel Service UPS shares have exhibited a consistent downward trend in recent months and currently trade near the 52-week low. At the closing price of $83.18 as of Oct. 13, the stock trades
Can LinkedIn Revenue Growth Accelerate Microsoft Stock's Upward Trend?
Microsoft’s MSFT LinkedIn is emerging as a key growth driver beyond its core cloud and AI businesses. In the fourth quarter of fiscal 2025, LinkedIn’s revenues rose 9% year over year, contributing
NFIB Small-Business Optimism Index Drops in September
At last, our speculations about economic growth in Q3 can be put to rest — new earnings numbers are beginning to hit the tape this morning from some of the biggest banks on Wall Street. We also get
3 Reasons to Hold WBD Stock Now Despite a 67.7% Year-to-Date Rally
Warner Bros. Discovery WBD has experienced a remarkable 67.7% surge year to date, outperforming the Zacks Broadcast Radio and Television industry and the Zacks Consumer Discretionary sector, which
Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?
AbbVie ABBV remains a dominant force in the immunology space, powered by the continued uptake of its two blockbuster medications, Skyrizi and Rinvoq. The robust demand for both drugs has helped the
Can BABA's Heavy Spending on Quick Commerce Yield Long-Term Return?
Alibaba's BABA aggressive bet on quick commerce is emerging as one of its most ambitious initiatives. In the first quarter of fiscal 2026, the segment delivered 12% year-over-year revenue growth
Corning Rises 62.8% in Three Months: Is the Stock Worth Buying?
Corning Incorporated GLW has gained 62.8% compared to the communications components industry’s growth of 64.2%. The stock has also outperformed the Zacks Computer & Technology sector and the S&P
AXP Gains Edge as RewardPay Debuts First-Ever Tax Pooling Rewards
American Express Company AXP is making a significant move in the B2B fintech arena as RewardPay launches the world’s first tax pooling payment system designed to reward businesses. This innovative
VNCE's DTC Sales Rise 5.5%: Can E-Commerce Keep Outpacing Wholesale?
Vince Holding Corp. (VNCE) delivered a strong performance in its Direct-to-Consumer (“DTC”) segment in the second quarter of fiscal 2025, with sales jumping 5.5% and successfully offsetting a
Consumer Beauty Sales Down 8%: Can Coty Revive Color Cosmetics?
Coty Inc.’s (COTY) Consumer Beauty segment ended fiscal 2025 on a downbeat note, with sales falling 8% year over year and operating profits slipping sharply as it contended with continued weakness
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
The drug and biotech sector bounced back this month after struggling this year due to tariff and pricing fears and broader macro headwinds. The recovery was propelled by Pfizer’s landmark
Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?
Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), has been driving the majority of the company’s revenues. The drug remains a key top-line driver for the company.
Livmarli, an orally
Tesla's Cybertruck Sales Collapse in Q3: What's Behind the Dip?
Electric vehicle (EV) giant Tesla TSLA posted record deliveries in the third quarter of 2025, but one of its most-hyped products—the Cybertruck— is turning into its biggest embarrassment yet.
Is Power Delivery Poised to Anchor MasTec's Infrastructure Growth?
MasTec, Inc. (MTZ) is strengthening position in the power infrastructure market as the Power Delivery segment emerges as a key growth pillar within its diversified operations. The business benefits
Do Options Traders Know Something About Equity Lifestyle Properties Stock We Don't?
Investors in Equity Lifestyle Properties ELS need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 21, 2025 $07.50 Put had some of the highest
Will Build-A-Bear's Balance Sheet Strength Fuel More Buybacks?
Build-A-Bear Workshop, Inc.’s BBW balance sheet strength provides it with enough headroom to continue aggressive buybacks. BBW ended the second quarter of fiscal 2025 with $39.1 million in cash
Is the Options Market Predicting a Spike in Consolidated Water Stock?
Investors in Consolidated Water Co. Ltd CWCO need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 21, 2025 $17.50 Put had some of the highest
DTE Energy Drives Forward With Major Clean Energy Investments
DTE Energy Company DTE continues to strengthen and expand its infrastructure through long-term capital investments aimed at improving service efficiency for its customers. At the same time, the
Can EMCOR's Prefabrication Drive Productivity and Margin Stability?
EMCOR Group, Inc. (EME) is advancing its operational strategy with a greater emphasis on prefabrication and design integration. The company has been expanding its prefabrication capacity across key
Tesla Q3 Earnings Preview: Will Record Deliveries Enhance Performance?
Tesla TSLA is set to release third-quarter 2025 results on Oct. 22, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings and revenues is pegged at 52 cents
3 Reasons to Hold BLZE Stock Now Despite a 56.8% Year-to-Date Rally
Backblaze BLZE has experienced a remarkable 56.8% surge year to date (YTD), outperforming the Zacks Internet-Software industry and Zacks Computer and Technology sector's return of 16.7% and 19.6%
Nebius Stock Surges 49% in a Month: Should You Hold or Offload?
Nebius Group N.V. NBIS is currently trading at $135.46, close to its 52-week high of $141.10. The stock has gained 48.9% in the past month, outperforming the Zacks Computer & Technology sector and
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
CorMedix CRMD has experienced significant growth in 2025, fueled by the strong uptake of the company’s lead marketed drug, DefenCath (Taurolidine + Heparin). The FDA approved CorMedix’s DefenCath in



